A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women.

Trial Profile

A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2011

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 24 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2011 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 20 May 2010 Planned end date changed from 1 Dec 2009 to 1 Aug 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top